Chargement en cours...
A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profil...
Enregistré dans:
| Publié dans: | Medicine (Baltimore) |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Lippincott Williams & Wilkins
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7598804/ https://ncbi.nlm.nih.gov/pubmed/33126339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022886 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|